KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant. PMID 41321117 · Clin Infect Dis · 2026-Feb-25 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8. PMID 41208546 · Clin Infect Dis · 2026-Feb-25 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. PMID 40874769 · Clin Infect Dis · 2026-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ensemble Deep Learning-Based High-Precision Framework for Breast Cancer Detection from Histopathological Images. PMID 41827929 · Diagnostics (Basel) · 2026-Feb-24 The record describes a methodological study in deep learning for breast cancer diagnosis from images. It is not a randomized clinical trial, lacks a drug intervention, and does not report any time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of cerebral oxygenation-guided resuscitation during immediate postnatal transition on brain injury and brain growth detected by MRI in very preterm neonates: a secondary outcome analysis of the multicenter randomized phase 3 clinical COSGOD III trial. PMID 41736052 · Ital J Pediatr · 2026-Feb-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial. PMID 41735896 · BMC Cancer · 2026-Feb-24 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Protocol for the development and testing of a web-based patient decision aid for early-stage breast cancer patients within a cancer centre care: a mixed-method approach. PMID 41734922 · BMJ Open · 2026-Feb-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis. PMID 41733109 · Arthritis Rheumatol · 2026-Feb-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology. PMID 41730847 · Signal Transduct Target Ther · 2026-Feb-24 The record describes a secondary analysis of a randomized trial evaluating molecular profiling (including DNA and RNA profiling) for guiding cancer therapy, with overall survival (OS) as a time-to-event endpoint. However, the trial is described as a 'randomized study' (NCT02152254) without explicit mention of Phase III/IIIb or Phase II/III status, and the analysis focuses on concordance between profiling methods and correlates gene expression with OS, not the primary efficacy of a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Lay Health Worker-Led Symptom Intervention and Acute Care Use in Older Adults With Cancer: A Randomized Clinical Trial. PMID 41468027 · JAMA · 2026-Feb-24 While this is an original, randomized oncology trial in humans, it does not meet two key eligibility criteria: 1) It lacks a time-to-event primary/key secondary efficacy endpoint (OS, PFS, DFS, etc.), and 2) The intervention is non-drug (symptom assessment via health workers).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial. PMID 41972014 · Liver Cancer · 2026-Feb-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Conventional Versus Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumors ≤ 20 mm: Study Protocol for a Multicenter Randomized Controlled Trial (D-CURE Trial). PMID 41745223 · Methods Protoc · 2026-Feb-23 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Ultrasound-guided retro-superior costotransverse ligament space block (RSSB) versus subcostal transversus abdominis plane block (TAPB) for postoperative analgesia in gastric cancer patients undergoing laparoscopic gastrectomy : a prospective randomized controlled trial. PMID 41724933 · BMC Anesthesiol · 2026-Feb-23 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Progression-Free Survival versus Overall Survival in Patients with PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP versus Placebo. PMID 41756446 · Res Sq · 2026-Feb-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis. PMID 41749963 · Cancers (Basel) · 2026-Feb-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis. PMID 41722967 · Lancet · 2026-Feb-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial. PMID 41655588 · Lancet · 2026-Feb-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. PMID 41653933 · Lancet · 2026-Feb-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases: A Randomized Controlled Trial]. PMID 41975647 · Zhongguo Fei Ai Za Zhi · 2026-Feb-20 Record meets criteria for oncology, human, randomized trial with drug intervention and time-to-event efficacy endpoints (PFS, OS) as primary/secondary outcomes. However, metadata does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. Without this confirmation, is_eligible must be false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study. PMID 41721054 · Pediatr Res · 2026-Feb-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. PMID 41512237 · J Clin Oncol · 2026-Feb-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. PMID 41499716 · J Clin Oncol · 2026-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. PMID 41363773 · J Clin Oncol · 2026-Feb-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia. PMID 41363770 · J Clin Oncol · 2026-Feb-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. PMID 41353787 · J Clin Oncol · 2026-Feb-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 4 Panel · risk unclear
Multi-modal integrated intervention combining exercise, anti-inflammatory, and dietary advice (MMIEAD) for adults with kidney cachexia: protocol for a mixed-methods feasibility cluster randomised controlled trial and process evaluation. PMID 41715172 · Pilot Feasibility Stud · 2026-Feb-19 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The RECLAIM adaptive platform trial for the evaluation of treatments for post-COVID condition in the Netherlands: core protocol. PMID 41715140 · Trials · 2026-Feb-19 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775. PMID 41714113 · J Immunother Cancer · 2026-Feb-19 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 6 Panel · risk unclear
Intravenous Fosfomycin in Complicated Urinary Tract Infection. PMID 41711122 · Ann Pharmacother · 2026-Feb-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. PMID 41363801 · N Engl J Med · 2026-Feb-19 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. PMID 41175364 · Blood · 2026-Feb-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. PMID 41749915 · Cancers (Basel) · 2026-Feb-18 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration). PMID 41714204 · Eur Urol Focus · 2026-Feb-18 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 5 Figure · 9 Panel · risk visible
Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease. PMID 41708985 · J Neurol · 2026-Feb-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness and Safety of Denosumab Versus Bisphosphonates in Elderly Patients with Cancer Bone Metastases: A Target Trial Emulation Study. PMID 41752980 · Life (Basel) · 2026-Feb-17 The record describes a retrospective observational cohort study (target trial emulation) comparing denosumab to bisphosphonates. While it is an oncology study with a time-to-event endpoint and drug intervention, it does not meet the core eligibility requirement of being a randomized controlled trial (Phase III/IIIb or Phase II/III). The abstract explicitly states it is a retrospective cohort study, not a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A conserved eIF1A+ luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. PMID 41707646 · Cell Rep Med · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Artificial Intelligence-based characterization of therapeutic response in fluid types and volumes influencing retinal function in neovascular age-related macular degeneration. PMID 41703113 · Sci Rep · 2026-Feb-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial. PMID 41702946 · Sci Rep · 2026-Feb-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Enhancing palliative care in intensive care units: protocol of EPIC, a controlled, cluster-randomised, non-blinded stepped-wedge design trial with crossover phase. PMID 41702660 · BMJ Open · 2026-Feb-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evidence-Based Self-Management Strategies for Fibromyalgia: Foundations for Digital Therapeutic Applications. PMID 41701966 · Interact J Med Res · 2026-Feb-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer. PMID 41537692 · Clin Cancer Res · 2026-Feb-17 The record is a secondary, biomarker-focused analysis (MRD) within a larger randomized trial (NADIM II). While it originates from a trial with oncology, human, randomized, drug intervention, and time-to-event components, this specific publication does not present the primary efficacy results of the parent trial. It is a secondary/prognostic analysis. The parent trial's phase is not explicitly confirmed in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial. PMID 41378996 · Clin Cancer Res · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. PMID 41378992 · Clin Cancer Res · 2026-Feb-17 The record describes a randomized, drug-intervention trial in human oncology with a time-to-event endpoint (PFS). However, two key criteria for eligibility cannot be definitively established from the provided metadata: 1) The formal trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the title, abstract, or metadata, though the title mentions 'late-phase' and the abstract notes it as a completed efficacy trial. 2) The report is a secondary/biomarker analysis ('exploratory analysis') of the GOG281/LOGS trial, not the primary formal-result report of the trial's main efficacy findings. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial. PMID 41364689 · JAMA · 2026-Feb-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial. PMID 41360717 · JAMA · 2026-Feb-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial. PMID 41335375 · Clin Cancer Res · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Perioperative Supplementation with Arginine and Omega-3 on Postoperative Complications in Patients Undergoing Gastrointestinal Cancer Surgery: A Pilot Open-Label Randomized Controlled Trial. PMID 41754168 · Nutrients · 2026-Feb-16 The study is a randomized, open-label, pilot trial in oncology patients, but it is not a Phase III/IIIb or Phase II/III trial. The primary and secondary endpoints (postoperative complications, mortality at 1 month, length of stay) are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS). The intervention is nutritional supplementation, not a drug intervention. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial-the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial. PMID 41698721 · BMJ Open · 2026-Feb-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Understanding the Unique Ethical Challenges in Randomized Controlled Trials of Delirium Interventions for Older Adults: A Rapid Review. PMID 41698182 · Anesth Analg · 2026-Feb-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Influence of gemcitabine combined with lobaplatin interventional embolization on vaginal flora and biofilm formation in patients with advanced cervical cancer. PMID 41697076 · Afr J Reprod Health · 2026-Feb-16 The study is an oncology randomized trial with a drug intervention, but the reported outcomes (vaginal flora changes, biofilm formation, and general 'curative effect') do not include a primary or key secondary time-to-event efficacy endpoint such as overall survival, progression-free survival, or Kaplan-Meier analysis. Therefore, it does not meet the eligibility criteria for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -